Infertility is a common problem in the U.S., affecting millions of couples who incur significant expense for fertility treatments. An integrated analysis of both partners including medical history, laboratory testing, imaging, and procedures to evaluate the genitourinary system is conducted to identify the cause of infertility.
Diagnosis
Indications for Testing
- Inability to achieve pregnancy
- Within 12 months with regular, unprotected intercourse
- Within 6 months with regular, unprotected intercourse
- If ≥35 years or
- With additional risk factors for infertility
- Known infertility
Laboratory Testing and Clinical Assessment
- Female
- Ovulation testing
- Serum progesterone
- Documents ovulation
- Collect approximately 1 week before start of menses (eg, day 21 of a 28-day cycle)
- Progesterone ≥3 ng/mL implies ovulation
- Serum progesterone
- Ovarian reserve testing (American Society for Reproductive Medicine (ASRM, 2015)
- Determine number and quality of eggs remaining in ovaries to be released and fertilized
- Adds more prognostic information; should not be sole criteria to determine treatments – limited predictive ability
- Available testing
- Anti-Mullerian hormone (AMH)
- Assess decreased ovarian reserve
- Relatively consistent throughout menstrual cycle – can be collected on any day
- High levels associated with polycystic ovarian syndrome (PCOS); low levels associated with poor reserve and poor response to ovarian stimulation
- Follicle stimulating hormone (FSH) and estradiol
- Measure on day 2-4 of menstrual cycle
- High FSH associated with difficulty conceiving and poor ovarian stimulation (required for in vitro fertilization [IVF] treatment)
- Fragile X carrier screening is recommended in individuals <40 years of age who receive an elevated FSH result or who have ovarian insufficiency without an apparent cause (American College of Obstetricians and Gynecologists [ACOG], 2019)
- Estradiol alone not a recommended test – only assists with interpretation of FSH
- Clomiphene citrate challenge
- Administer clomiphene citrate 100 mg daily
- Measure FSH day 3 and day 10 of cycle
- Anti-Mullerian hormone (AMH)
- Further testing for etiology of anovulatory cycles
- Serum prolactin
- Evaluate in women with irregular menses, galactorrhea, or other signs or hyperprolactinemia
- If prolactin is elevated and computed tomography (CT)/magnetic resonance imaging (MRI) of sella is negative, consider macroprolactin testing
- Do not perform prolactin testing as part of routine infertility evaluation in women with regular menses (Choosing Wisely, ASRM, 2015)
- Thyroid stimulating hormone (TSH)
- Evaluate for hypothyroidism
- Correction can restore regular cycles
- Hyperandrogenism/PCOS
- Testosterone
- Use test for children and females (done by mass spectrometry or liquid chromatography tandem mass spectrometry [LC-MS/MS]) – able to detect low levels of testosterone
- Use for evaluation of suspected PCOS
- Signs and symptoms – acne, hirsutism, irregular periods, male pattern baldness
- Patient will have anovulatory cycles
- Testosterone
- Serum prolactin
- Ovulation testing
- Male
- Sperm analysis
- Assess spermatic function
- Semen analysis of at least 2 specimens (after 2-3 days of abstinence)
- If repeat analysis required, repeat after 3 months due to 2 month sperm regeneration time
- Up to 40% of subfertile men have normal sperm analysis
- Normal semen parameters – 5th percentiles (95% confidence intervals in parentheses) (Cooper, WHO, 2010)
- Volume – ≥1.5 mL (1.4-1.7)
- pH – ≥7.2
- Sperm concentration – ≥15x106 spermatozoa/mL (12-16)
- Total sperm count – ≥39x106/ejaculate (33-46)
- Motility – within 60 minutes of ejaculation
- Total motility – ≥40% (38-42)
- Progressive motility – ≥32% (31-34)
- High viability with a low motility suggestive of structural defects (eg, primary ciliary dyskinesia)
- Vitality – ≥58% live (55-63)
- Morphology – ≥4% normal forms (3-4)
- Testosterone (see Hypogonadism topic)
- Assess androgen status using testosterone
- Morning total testosterone is appropriate initial test
- Most useful if oligospermia or azoospermia noted on semen analysis
- Assess androgen status using testosterone
- FSH and luteinizing hormone (LH)
- In combination with testosterone levels, assists with determination of primary or secondary hypogonadism
- Additional analysis – consider if initial screen is negative and other signs and symptoms indicate reasons for testing
- Ferritin – elevated iron levels may indicate hereditary hemochromatosis
- TSH – hypothyroidism
- CBC, sexually transmitted infections (STI) testing – evaluate for infectious disease
- Testing for pituitary tumor
- Prolactin
- Growth hormone – see Growth Hormone Deficiency topic for appropriate stimulation testing
- Genetic testing
- Warranted when sperm density <5x106/mL or when nonobstructive azoospermia or clinical suspicion present
- Karyotyping
- Klinefelter syndrome (XXY) is most common abnormality (see Hypogonadism, Background)
- Associated with normal semen volume but low sperm
- Typically low testosterone with elevated FSH
- Klinefelter syndrome (XXY) is most common abnormality (see Hypogonadism, Background)
- Y chromosome microdeletion
- Typically normal semen volume, low sperm count, normal or elevated FSH
- Not detected with standard karyotyping
- Deletion is in azoospermia factor (AZF) regions
- Associated with successful assisted reproductive technology
- CFTR gene analysis to exclude cystic fibrosis
- When vas deferens absent
- Typically low semen volume
- Sperm analysis
Differential Diagnosis
See Etiology in Background.
Background
Epidemiology
- Prevalence – 10-15% of couples in U.S. (~2 million couples)
- Definition – inability to conceive after 12 months of regular, unprotected intercourse
Etiology
- Female factors – 30-40% of cases
- Ovarian dysfunction
- Aging
- Endocrine disorders
- Polycystic ovarian syndrome
- Premature ovarian failure
- Single ovary
- Previous ovarian surgery
- History of chemotherapy or radiation
- Tubal factors
- Obstruction – history of pelvic inflammatory disease, tubal pregnancy, tubal or pelvic surgery
- Endometriosis
- Uterine/cervical factors – uncommon etiologies
- Congenital anomaly
- Fibroids
- Polyps
- Poor cervical mucous quality
- Lifestyle
- Endocrine/metabolic disorders
- Congenital adrenal hyperplasia
- Virilizing tumors
- Adrenal failure
- Cushing syndrome
- Hypo/hyperthyroidism
- Diabetes mellitus
- X chromosome abnormalities
- Genetic disease
- Ovarian dysfunction
- Male factors – 30-40% of cases
- Primary/secondary hypogonadism
- Orchitis – usually infectious (eg, mumps)
- Altered sperm (eg, cystic fibrosis)
- Y chromosome abnormalities/microdeletions
- Trauma
- Exposure to toxic agents (eg, chemotherapy, radiation)
- Testicular tumor
Clinical Presentation
- Female
- Irregular menses
- Galactorrhea
- Signs of hyperandrogenism (eg, hirsutism)
- Obesity or underweight
- Male
- Varicocele or hydrocele
- Signs of androgen deficiency
- Small testes
- Signs of infection (eg, epididymitis)
- Obstruction/absence of the ejaculatory ducts
- Testicular tumor
ARUP Laboratory Tests
Aid in the workup of suspected infertility, detection of ovulation, and assessment of the luteal phase
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Assist in determining etiology of infertility
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Estimate ovarian reserve
Quantitative Enzyme-Linked Immunosorbent Assay
Aid in determining etiology of ovulatory or androgen dysfunction
Quantitative Electrochemiluminescent Immunoassay
Use this immunoassay to measure estradiol in adult premenopausal cisgender females and individuals on estrogen hormone therapies
Not recommended when low estradiol concentrations, such as those found in children, cisgender males, and postmenopausal females, are expected, or for monitoring antiestrogen (eg, aromatase inhibitor) therapy; the preferred estradiol test in these cases is Estradiol (Adult Males, Children, Postmenopausal Females, or Individuals on Estrogen-Suppressing Hormone Therapy)
Not recommended in the evaluation of estradiol status for individuals with protein-binding abnormalities or individuals on hormonal contraception; the preferred estradiol test for these individuals is Estradiol, Free, by Dialysis and Mass Spectrometry
Quantitative Chemiluminescent Immunoassay
Screen for anterior pituitary tumor
Determine if elevated prolactin is cause of infertility
Quantitative Chemiluminescent Immunoassay
Exclude prolactinoma
Quantitative Chemiluminescent Immunoassay
Use to assess thyroid function
Quantitative Electrochemiluminescent Immunoassay
Provides a calculated value for free testosterone concentration using total testosterone measured by mass spectrometry
May be used to evaluate hyperandrogenism in children and cisgender females, monitor testosterone-suppressing hormone therapies (eg, antiandrogens or estrogens), evaluate testosterone status in individuals with protein-binding abnormalities, or evaluate hypogonadism in cisgender males
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry/Electrochemiluminescent Immunoassay/Calculation
Determine if etiology of infertility is male related
Cornerstone evaluation of male infertility
Limitations
Time-sensitive test
2 semen samples should be evaluated (collected 7 days apart; 3 months after any febrile illness)
Samples are collected after a period of abstinence of >48 hours, but <7 days
Specimens should be analyzed within 1 hour of collection
Use this immunoassay to evaluate hypogonadism in cisgender males and to monitor testosterone hormone therapies
Not recommended when low testosterone concentrations, such as those found in children and cisgender females, are expected; for these individuals, testing by mass spectrometry is recommended; refer to Testosterone (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)
Free or bioavailable testosterone measurements may provide supportive information
Quantitative Electrochemiluminescent Immunoassay
Aid in determining etiology of ovulatory or androgen dysfunction
Quantitative Electrochemiluminescent Immunoassay
Aid in determining cause of azoospermia or oligospermia
Predict effectiveness of assisted reproductive technologies in men with Y chromosome microdeletions
Clinical sensitivity: ~5-10% for men with nonobstructive azoospermia or severe oligospermia
Breakpoints of identified microdeletions will not be determined
Variants within individual genes included in the azoospermia factor (AZF) regions will not be detected
Male infertility due to causes other than the common Y chromosome microdeletions tested will not be detected
Polymerase Chain Reaction/Electrophoresis
Confirm diagnosis of a known aneuploid syndrome or detect a chromosome translocation
This test is intended for constitutional studies; refer to cytogenomic SNP microarray for the PREFERRED FIRST-TIER test for intellectual disability, multiple anomalies, and autism-spectrum disorders
For chromosome analysis to evaluate for an oncology finding, order chromosome analysis, leukemic blood
Giemsa Band
For individuals with suspected cystic fibrosis (CF) but without 2 pathogenic variants detected by the CF expanded variant test
Massively Parallel Sequencing/Sequencing
Order for organisms for which no stand-alone cultures are available
Use for uncommon organisms such as Streptobacillus moniliformis, Haemophilus ducreyi, and others; Neisseria gonorrhoeae specimens not approved for nucleic acid amplification testing (NAAT)
Culture
Not recommended for routine detection of Chlamydia trachomatis
Use to detect C. trachomatis in medicolegal settings and to assess suspected treatment failure
May be considered for anatomic locations for which amplified testing has not been validated
NAAT is recommended for detection of C. trachomatis from endocervical or urethral specimens; refer to C. trachomatis by transcription-mediated amplification (TMA)
Cell Culture/Immunofluorescence
Preferred test for screening and monitoring of thyroid function
Quantitative Chemiluminescent Immunoassay
Use this mass spectrometry test to measure a wide range of testosterone concentrations
Most useful when low concentrations are expected, regardless of the patient’s sex assigned at birth
Use to monitor testosterone-suppressing hormone therapies (eg, antiandrogens or estrogens)
Free or bioavailable testosterone measurements may provide supportive information
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Provides a calculated value for bioavailable testosterone concentration using total testosterone measured by mass spectrometry
May be used to evaluate hyperandrogenism in children and cisgender females, monitor testosterone-suppressing hormone therapies (eg, antiandrogens or estrogens), evaluate testosterone status in individuals with protein-binding abnormalities, or evaluate hypogonadism in cisgender males
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry/Electrochemiluminescent Immunoassay/Calculation
Provides a calculated value for free testosterone concentration using total testosterone measured by immunoassay. Use to evaluate hypogonadism in cisgender males with a total testosterone concentration at the lower limit of normal
May be used to evaluate testosterone status in individuals with protein-binding abnormalities or to monitor testosterone hormone therapies
Not recommended when low testosterone concentrations, such as those found in children and cisgender females, are expected; for these individuals, testing by mass spectrometry is recommended; refer to Testosterone, Free (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)
Quantitative Electrochemiluminescent Immunoassay/Calculation
Provides a calculated value for bioavailable testosterone concentration using total testosterone measured by immunoassay
Use to evaluate hypogonadism in cisgender males with a total testosterone concentration at the lower limit of normal
May be used to evaluate testosterone status in individuals with protein-binding abnormalities or to monitor testosterone hormone therapies
Not recommended when low testosterone concentrations, such as those found in children and cisgender females, are expected; for these individuals testing by mass spectrometry is recommended; refer to Testosterone, Bioavailable and Total, Includes Sex Hormone-Binding Globulin (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)
Quantitative Electrochemiluminescent Immunoassay/Calculation
Provides a calculated value for free testosterone concentration using total testosterone measured by immunoassay
Use to evaluate hypogonadism in cisgender males with a total testosterone concentration at the lower limit of normal
May be used to evaluate testosterone status in individuals with protein-binding abnormalities or to monitor testosterone hormone therapies
Not recommended when low testosterone concentrations, such as those found in children and cisgender females, are expected; for these individuals, testing by mass spectrometry is recommended; refer to Testosterone, Free and Total, Includes Sex Hormone-Binding Globulin (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy)
Quantitative Electrochemiluminescent Immunoassay/Calculation
May be used for infertility evaluation
Use to differentiate ovarian tumor with normal CA 125 as stromal or mucinous epithelial tumor
May be used for monitoring recurrence of stromal ovarian tumors
Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Indicator of fetal well-being and placental function
Quantitative Chemiluminescent Immunoassay
Use to directly measure free estradiol
May be used to evaluate estradiol status for individuals with protein-binding abnormalities or individuals on hormonal contraception
Quantitative Equilibrium Dialysis/High Performance Liquid Chromatography-Tandem Mass Spectrometry
Useful to ensure the highest chance of obtaining meaningful results from fetal specimens
When tissue culture is unsuccessful or if the results of the chromosome analysis are normal, then testing reflexes to genomic microarray
Giemsa Band/Genomic Microarray (Oligo-SNP Array)
Use for intrauterine fetal demise or stillbirth when further cytogenetic analysis is desired, pregnancy loss or termination in the presence of fetal anomalies, further characterization of fetal chromosomal abnormalities seen by conventional cytogenetic methods, multiple fetal losses of unknown etiology, or POC samples that fail to grow in culture
Genomic Microarray (Oligo-SNP Array)
References
17884905
Balen AH, Rutherford AJ. Management of infertility. BMJ. 2007;335(7620):608-611.
18721657
Brassard M, AinMelk Y, Baillargeon JP. Basic infertility including polycystic ovary syndrome. Med Clin North Am. 2008;92(5):1163-1192, xi.
24286774
Centola GM. Semen assessment. Urol Clin North Am. 2014;41(1):163-7.
Choosing Wisely
Choosing Wisely. An initiative of the ABIM Foundation. [Accessed: Dec 2020]
19934213
Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16(3):231-245.
22828101
Fritz MA. The modern infertility evaluation. Clin Obstet Gynecol. 2012;55(3):692-705.
23503952
Gudeloglu A, Parekattil SJ. Update in the evaluation of the azoospermic male. Clinics (Sao Paulo). 2013;68(Suppl 1):27-34.
31135764
Infertility workup for the women's health specialist: ACOG Committee Opinion, Number 781. Obstet Gynecol. 2019;133(6):e377-e384.
20205744
Kamel RM. Management of the infertile couple: an evidence-based protocol. Reprod Biol Endocrinol. 2010;8:21.
19793843
La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113-130.
17641086
Lewis SEM. Is sperm evaluation useful in predicting human fertility? Reproduction. 2007;134(1):31-40.
25822387
Lindsay TJ, Vitrikas KR. Evaluation and treatment of infertility. Am Fam Physician. 2015;91(5):308-314.
17055838
Practice Committee of the American Society for Reproductive Medicine. Optimal evaluation of the infertile female. Fertil Steril. 2006;86(5 Suppl 1):S264-S267.
19007652
Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology. Evaluation of the azoospermic male. Fertil Steril. 2008;90(5 Suppl):S74-S77.
25585505
Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9-e17.
25936238
Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103(6):e44-50.
28228319
Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Reproductive Endocrinology and Infertility. Fertil Steril. 2017;107(1):52-58.
25597249
Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile male: a committee opinion. Fertil Steril. 2015;103(3):e18-25.
18423238
Robins JC, Carson SA. Female fertility: what every urologist must understand. Urol Clin North Am. 2008;35(2):173-181, vii.
19745794
Schlegel PN. Evaluation of male infertility. Minerva Ginecol. 2009;61(4):261-83.
24286765
Smith RP, Coward RM, Lipshultz LI. The office visit. Urol Clin North Am. 2014;41(1):19-37.
18504696
Van Voorhis BJ. Ultrasound assessment of the ovary in the infertile woman. Semin Reprod Med. 2008;26(3):217-222.
Medical Experts
Bayrak-Toydemir

Straseski

Reflex pattern: if the thyroid stimulating hormone is outside the reference interval, then free thyroxine (T4) testing will be added